These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 16136028)
1. Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. Geoerger B; Vassal G; Doz F; O'Quigley J; Wartelle M; Watson AJ; Raquin MA; Frappaz D; Chastagner P; Gentet JC; Rubie H; Couanet D; Geoffray A; Djafari L; Margison GP; Pein F Br J Cancer; 2005 Sep; 93(5):529-37. PubMed ID: 16136028 [TBL] [Abstract][Full Text] [Related]
2. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061 [TBL] [Abstract][Full Text] [Related]
3. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959 [TBL] [Abstract][Full Text] [Related]
4. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Ranson M; Middleton MR; Bridgewater J; Lee SM; Dawson M; Jowle D; Halbert G; Waller S; McGrath H; Gumbrell L; McElhinney RS; Donnelly D; McMurry TB; Margison GP Clin Cancer Res; 2006 Mar; 12(5):1577-84. PubMed ID: 16533784 [TBL] [Abstract][Full Text] [Related]
5. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030 [TBL] [Abstract][Full Text] [Related]
6. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. Rubie H; Geoerger B; Frappaz D; Schmitt A; Leblond P; Ndiaye A; Aerts I; Le Deley MC; Gentet JC; Paci A; Chastagner P; Dias N; Djafari L; Pasquet M; Chatelut E; Landman-Parker J; Corradini N; Vassal G Eur J Cancer; 2010 Oct; 46(15):2763-70. PubMed ID: 20558056 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788 [TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672 [TBL] [Abstract][Full Text] [Related]
15. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. Zustovich F; Lombardi G; Della Puppa A; Rotilio A; Scienza R; Pastorelli D Anticancer Res; 2009 Oct; 29(10):4275-9. PubMed ID: 19846986 [TBL] [Abstract][Full Text] [Related]
17. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678 [TBL] [Abstract][Full Text] [Related]
18. [Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases]. Zhang JP; Shi HL; Sai K; Yue WY; Mu YG; Zhang XH; Chen ZP Ai Zheng; 2006 Dec; 25(12):1533-7. PubMed ID: 17166381 [TBL] [Abstract][Full Text] [Related]
19. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Zauderer MG; Drilon A; Kadota K; Huberman K; Sima CS; Bergagnini I; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Riely GJ; Kris MG; Krug LM; Pietanza MC Lung Cancer; 2014 Nov; 86(2):237-40. PubMed ID: 25194640 [TBL] [Abstract][Full Text] [Related]
20. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]